nan
Artificial Intelligence In Manufacturing And Supply Chain Market Forecast Highlighting Growth From $0.7 Billion To $0.92 Billion
The gene silencing therapeutics market size has demonstrated rapid expansion in recent years. It is projected to grow from $4 billion in 2025 to $4.64 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.1%. The growth witnessed in the past period can be ascribed to the growing prevalence of genetic disorders, increasing investment in molecular medicine research, a rising demand for targeted therapeutic approaches, the expanding clinical success of RNA based therapies, and an increasing focus on rare disease treatment development.
The gene silencing therapeutics market is projected to experience substantial growth in the next few years, with its size anticipated to reach $8.49 billion by 2030, expanding at a compound annual growth rate (CAGR) of 16.3%. This growth during the forecast period can be attributed to the advancing commercialization of gene silencing therapeutics, a growing pipeline of precision genetic medicines, increasing regulatory approvals for novel gene therapies, expanding applications across oncology and neurological disorders, and the rising adoption of personalized medicine strategies. Noteworthy trends in the forecast period include the increasing adoption of RNA interference-based therapeutics, the growing development of antisense oligonucleotide treatment platforms, a rising focus on targeted gene expression regulation for rare diseases, the expansion of advanced delivery technologies for gene silencing therapeutics, and increasing clinical research activity in next-generation gene silencing therapies.
Download A Free Sample Report For Comprehensive Market Insights:
Gene Silencing Therapeutics Market Growth Momentum: Which Factors Are Influencing Demand?
The expanding emphasis on personalized medicine is anticipated to stimulate expansion within the gene silencing therapeutics market in the future. This healthcare strategy tailors medical treatments by considering an individual’s genetic profile, biomarkers, and specific disease characteristics, thereby enhancing treatment effectiveness and clinical outcomes. Its rising prominence is propelled by advancements in genetic and molecular profiling technologies that allow for treatments designed for specific patient attributes. Gene-silencing therapeutics complement personalized medicine by specifically targeting disease-causing genes using an individual’s genetic profile, leading to more accurate treatment, greater efficacy, and reduced adverse effects. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that in 2023, the FDA granted approval to 16 new personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the growing adoption of personalized medicine is stimulating expansion within the gene silencing therapeutics market.
Artificial Intelligence In Manufacturing And Supply Chain Market Segment Landscape: Which Areas Lead Market Development?
The gene silencing therapeutics market covered in this report is segmented –
1) By Technology: Ribonucleic Acid Interference; Antisense Oligonucleotides; Other Technologies
2) By Delivery Method: Nanoparticles; Viral Vectors; Liposomes; Other Delivery Methods
3) By Application: Oncology; Genetic Disorders; Infectious Diseases; Neurological Disorders; Other Applications
4) By End User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users
Subsegments:
1) By Ribonucleic Acid Interference: Small Interfering Ribonucleic Acid Therapeutics; Short Hairpin Ribonucleic Acid Therapeutics; Micro Ribonucleic Acid Therapeutics; Dicer Substrate Small Interfering Ribonucleic Acid Therapeutics
2) By Antisense Oligonucleotides: Exon Skipping Oligonucleotides; Splice Switching Oligonucleotides; Gapmer Antisense Oligonucleotides; Phosphorothioate Oligonucleotides; Peptide Conjugated Oligonucleotides
3) By Other Technologies: Aptamer Based Gene Silencing; Zinc Finger Nuclease Technologies; Transcription Activator Like Effector Nuclease Based Gene Silencing; Messenger Ribonucleic Acid Degradation Technologies; Epigenetic Gene Silencing Technologies
Innovations In Kidney-Targeted Gene Silencing Technologies Advance Precision Genetic Medicine Development
Major companies operating in the gene silencing therapeutics market are adopting advanced RNA delivery platforms, such as ligand-conjugated siRNA technologies, to improve tissue-specific targeting and enhance therapeutic precision for genetic and renal diseases. Ligand-conjugated siRNA technologies refer to specialized RNA delivery approaches that attach targeting ligands to small interfering RNA molecules to enable receptor-mediated uptake and selective gene silencing in specific tissues or cell types. For instance, in June 2025, Judo Bio, Inc., a US-based biotechnology company, launched with $100 million in Series A financing led by Atlas Venture, TCG, and Droia Ventures to advance precision genetic medicines targeting kidney diseases. The company introduced its STRIKE (Selectively Targeting RNA Into Kidney) platform, a ligand-conjugated siRNA delivery technology engineered for receptor-mediated uptake into kidney cell types, enabling selective gene silencing in renal tissues. The platform’s initial megalin-STRIKER programs are designed to deliver small interfering RNA therapeutics to proximal tubule cells in the kidney to silence mRNA expression of solute carrier proteins associated with systemic and renal diseases.
Gene Silencing Therapeutics Market Competitive Analysis Of Major Industry Participants
Major companies operating in the gene silencing therapeutics market are Novartis AG; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Silence Therapeutics plc; Wave Life Sciences Ltd.; ProQR Therapeutics N.V.; Dyne Therapeutics Inc.; Stoke Therapeutics Inc.; Arbutus Biopharma Corporation; PepGen Inc.; Sirnaomics Ltd.; OliX Pharmaceuticals Inc.; Benitec Biopharma Inc.; ADARx Pharmaceuticals Inc.; Tune Therapeutics Inc.; Sylentis S.A.; Isarna Therapeutics GmbH; City Therapeutics Inc.; Arcturus Therapeutics Holdings Inc.; Novo Nordisk; Moderna Inc.; BioNTech SE; Sanofi
Access The Complete Gene Silencing Therapeutics Market Report:
Gene Silencing Therapeutics Market Regional Analysis And Leading Geography
North America was the largest region in the gene silencing therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene silencing therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.